Dr Mikael von Euler moves to Oncos Therapeutics
pharmafile | February 10, 2011 | Appointment | Research and Development | Dr Mikael von Euler, Oncos Therapeutics, appointment, research and development
Finnish biotech company Oncos Therapeutics has appointed Dr Mikael von Euler as chief medical officer.
He has more than 20 years of pharma experience, most recently at Roche where he was cluster head for the company’s HER2 Franchise.
Prior to this Mikael was VP of oncology MDC, Europe, at GlaxoSmithKline and before this held several senior clinical development roles at AstraZeneca, including director of clinical strategy in Japan and global product director oncology.
Oncos is developing novel cancer therapeutics based on its next generation oncolytic viruses, and the company said Mikael would have a key role in turning its work to date into a clinical development programme.
“Oncos has already treated over 200 patients across different solid tumour types with many different formulations of its next generation oncolytic viruses – and this has created a unique platform of patient response data from which the company can now build the highest quality data-driven clinical development programme,” Mikael said.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






